WHAT IS CLAIMED IS:

1. A complex of formula (I) or a solvate thereof:



Formula (I)

wherein n is 1 to 4.

2. The complex or the solvate thereof according to claim 1, wherein n is 2.

3. The complex or the solvate thereof according to claim 2, wherein the solvate is a methanol solvate, an ethanol solvate, or a hydrate.

4. The complex or the solvate thereof according to claim 2, wherein the complex or the solvate is an ethanol solvate having a polymorph A, wherein an X-ray powder diffraction pattern thereof, measured with Cu-Kα radiation, has diffraction peaks at about 4.9±0.2, 9.8±0.2, and 12.0±0.2 represented by 2θ.

5. The complex or the solvate thereof according to claim 4, wherein the X-ray powder diffraction pattern of the polymorph A is substantially as shown in Fig. 1.

6. The complex or the solvate thereof according to claim 2, wherein the complex or the solvate thereof is a methanol solvate having a polymorph B, wherein an X-ray powder diffraction pattern thereof, measured with Cu-Kα radiation, has diffraction peaks at about 10.9±0.2, 12.6±0.2, and 13.7±0.2 represented by 2θ.

7. The complex or the solvate thereof according to claim 6, wherein the X-ray powder diffraction pattern of the polymorph B is substantially as shown in Fig. 2.

8. The complex or the solvate thereof according to claim 2, wherein the complex or the solvate thereof is a hydrate having a polymorph C, wherein an X-ray powder diffraction pattern thereof, measured with Cu-Kα radiation, has diffraction peaks at about 10.8±0.2, 12.6±0.2, and 13.7±0.2 represented by 2θ.

9. The complex or the solvate thereof according to claim 8, wherein the X-ray powder diffraction pattern of the polymorph C is substantially as shown in Fig. 3.

10. The complex or the solvate thereof according to claim 1 or 2, wherein the complex or the solvate thereof is in an amorphous form.

11. The complex or the solvate thereof according to any one of claims 1 to 10, wherein the complex or the solvate thereof has a median particle size D_{50} in a range of 0.1 to 50 μm.

12. A method for preparing the complex or the solvate thereof according to any one of claims 1 to 3, comprising mixing bupivacaine and pamoic acid in a molar ratio of greater than 1:1 and less than or equal to 4:1 in a solvent and heating the resultant mixture, wherein the solvent is selected from a group consisting of methanol, acetone, ethanol, dimethylsulfoxide, N,N-dimethylformamide, water and a mixed solvent thereof.

13. The method according to claim 11, wherein the molar ratio between the bupivacaine and the pamoic acid is greater than or equal to 2:1.

14. A method for preparing the complex or the solvate thereof according to claim 4, comprising mixing bupivacaine and pamoic acid in a molar ratio of greater than or equal to 2:1 in a solvent and heating the resultant mixture, wherein the solvent comprises ethanol and optionally comprises one or more selected from a group consisting of methanol, acetone, dimethylsulfoxide, N,N-dimethylformamide and water.

15. A method for preparing the complex or the solvate thereof according to claim 6, comprising mixing bupivacaine and pamoic acid in a molar ratio of greater than or equal to 2:1 in a solvent and heating the resultant mixture, wherein the solvent comprises methanol and optionally comprises one or more selected from a group consisting of acetone, dimethylsulfoxide, N,N-dimethylformamide and water.

16. A method for preparing the complex or the solvate thereof according to claim 8, comprising converting the complex or the solvate thereof according to claim 4, 6 or 10 into a bis(bupivacaine) pamoate hydrate in water.

17. A method for preparing the complex according to claim 10, comprising converting the complex or the solvate thereof according to claim 4, 6 or 8 into amorphous powders by heating it to

remove the solvent; or preparing amorphous powders from bupivacaine and pamoic acid by a melting method.

18. A pharmaceutical composition comprising a pharmaceutically effective amount of the complex or the solvate thereof according to any one of claims 1 to 11 and a pharmaceutically acceptable excipient.

19. The pharmaceutical composition according to claim 18, wherein the pharmaceutically acceptable excipient comprises one or more selected from a group consisting of a suspending agent, a surfactant, a filler, a preservative, an isoosmotic adjusting agent, a pH modifier, a buffer and water.

20. The pharmaceutical composition according to claim 19, wherein the complex or the solvate thereof is solid particles having a median particle size D_{50} in a range of 0.2 to 20 μm.

21. The pharmaceutical composition according to claim 18, wherein the pharmaceutical composition is a suspension, and comprises 1 to 300 mg of the complex or the solvate thereof per 1 mL of the suspension.

22. The pharmaceutical composition according to claim 18, wherein the pharmaceutical composition comprises no water, and comprises 10 wt% or more of the complex or the solvate thereof.

23. The pharmaceutical composition according to claim 19, wherein the suspending agent is one or more selected from a group consisting of carboxymethyl cellulose or a sodium salt thereof, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, sodium hyaluronate, and polyvinylpyrrolidone; the surfactant is one or more selected from a group consisting of polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80, polysorbate-85, polyoxyethylated castor oil, polyoxyethylated hydrogenated castor oil, lecithin, polyvinylpyrrolidone, polyethylene glycols, polyethylene oxide and polypropylene oxide ethers, and polyethylene glycol 15-hydroxystearate; the filler is one or more selected from a group consisting of mannitol, sucrose, maltose, xylitol, lactose, glucose, starch and sorbitol; the preservative is one or more selected from a group consisting of benzoic acid, benzyl alcohol, butylated hydroxytoluene ether, butylated hydroxytoluene, chlorobutanol, gallate, hydroxybenzoate, ethylenediamine tetraacetic acid and a salt thereof, chlorocresol, m-cresol, methylbenzethonium chloride, myristyl-γ-methylpyridine chloride, phenylmercuric acetate, and thimerosal; the isoosmotic adjusting agent is one or more selected from a group consisting of mannitol, sorbitol, sodium chloride, glucose, sucrose,

fructose, and lactose; and the buffer is one or more selected from a group consisting of a phosphate, an acetate, a citrate, and a tris(hydroxymethyl)aminomethane buffer solution.

24. Use of the pharmaceutical composition according to any one of claims 18 to 23 in the manufacture of a medicament for the prevention or treatment of surgical pain, intraoperative pain, and postsurgical pain.

25. The use according to claim 24, wherein the pharmaceutical composition is to be administrated via subcutaneous injection, intracutaneous injection, or intramuscular injection.